NE Rhaleb, N Rouissi, D Jukic, D Regoli… - European journal of …, 1992 - Elsevier
Abstract HOE 140 (D-Arg-[Hyp 3, Thi 5, D-Tic 7, Oic 8] bradykinin, a new B 2 antagonist, was
compared to R-493 (D-Ar [Hyp 3-D-Phe 7, Leu 8] bradykinin) with respect to inhibition of the
responses of seven isolated smooth muscle preparations to bradykinin. R-493 was found to …

…, V Pestellini, CA Maggi, R Patacchini, D Regoli… - European journal of …, 1990 - Elsevier
The classical approach used in the development of substance P (SP) antagonists, ie the
introduction of multiple 3-tryptophan (D-Trp), was successfully extended to neurokinin A
(NKA). Thus, a new NK-2-selective tachykinin receptor antagonist, namely [Tyr 5, D-Trp 6, 8 …

…, W Adams Jr, T Cash, T Yellin, D Regoli - Journal of medicinal …, 1988 - ACS Publications
The synthesis and biological activities of angiotensin II (All) analogues are described and
compared to the literature. D-Amino acid substitution was employed to search for novel All
antagonists that would also display reduced partial agonist activity. Substitution of D-amino …

…, S Salvadori, RK Reinscheid, D Regoli… - … of Pharmacology and …, 2009 - ASPET
Neuropeptide S (NPS) was identified as the endogenous ligand of an orphan receptor now
referred to as the NPS receptor (NPSR). In the frame of a structure-activity study performed
on NPS Gly5, the NPSR ligand [d-Cys (tBu) 5] NPS was identified.[d-Cys (tBu) 5] NPS up to …

[CITATION][C] Pharmacology of bradykinin and related kinins.

D Regoli, J Barabe - Pharmacological reviews, 1980 - ASPET
THE history of kinins began in 1909 when two French surgeons, Abelous and Barclier(2),
observed a transient fall of blood pressure in man after the intravenous injection of fractions
extracted from human urine. In 1928, Frey and Kraut(157) attributed the hypotensive effect of …

[CITATION][C] Receptors and antagonists for substance P and related peptides.

D Regoli, A Boudon, JL Fauchere - Pharmacological reviews, 1994 - ASPET
III. Neurokinin pharmacology A. In vivo activities B. Involvement of neurokinins in pain
transmission C. Regulation of cardiovascular functions D. Secretion of endogenous agents
from various cells E. In vitro activities: receptor pharmacology F. Molecular biology of …

[CITATION][C] Pharmacology of angiotensin

D Regoli, WK Park, F Rioux - Pharmacological Reviews, 1974 - ASPET
Angiotensin is a natural octapeptide which is presumed to act both as local tissue hormone,
within the kidney(32, 171, 242, 278, 319) and as true hormone, on the peripheral vessels
and the adrenal glands (42, 228, 330). Systematic pharmacological studies of this peptide …

D Regoli, G Drapeau, S Dion, P D'Orléans-Juste - Life sciences, 1987 - Elsevier
The three neurokinins identified in mammals, substance P, neurokinin A and neurokinin B,
as well as their C-terminal biologically active fragments, have been used to characterize the
responses of a variety of isolated organs. Three preparations selective either for substance …

D Regoli, G Drapeau, S Dion, R Couture - Trends in pharmacological …, 1988 - Elsevier
The neurokinin system is replete with a multiplicity of endogenous ligands (substance P,
neurokinin A, neurokinin B) and their receptors (NK 1, NK 2 and NK 3). Neurokinin receptors
have previously been studied almost exclusively with natural—but non-selective—agonists …

…, A Rizzi, S Salvadori, D Regoli - British journal of …, 2000 - Wiley Online Library
Nociceptin (NC), alias Orphanin FQ, has been recently identified as the endogenous ligand
of the opioid receptor‐like 1 receptor (OP4). This new NC/OP4 receptor system belongs to
the opioid family and has been characterized pharmacologically with functional and binding …